The latest data suggests that, in patients with type 2 diabetes and chronic kidney disease, Ozempic slashes the risk of kidney failure, substantial loss of kidney function, or death from kidney ...

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, end-stage kidney disease and cardiovascular disease-caused death for patients ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks ...

The FDA has approved Novo Nordisk’s Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic ...

The Food and Drug Administration (FDA) on Tuesday approved Ozempic (semaglutide) to reduce the risk of complications and death in adults with both type 2 diabetes and chronic kidney disease. This ...

It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.

FDA approves Ozempic to reduce risk of kidney disease progression, cardiovascular death By Natalie Dreier, Cox Media Group National Content Desk January 29, 2025 at 11:48 am EST ...

(CNN) — Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated ...